Glucose metabolism in patients with essential hypertension

被引:112
|
作者
García-Puig, J
Ruilope, LM
Luque, M
Fernández, J
Ortega, R
Dal-Ré, R
机构
[1] Hosp Univ La Paz, Gen Hosp, Med Interna Serv, Div Internal Med, Madrid 28046, Spain
[2] Hosp Univ 12 Octubre, Hypertens Unit, Madrid, Spain
[3] Hosp Clin Univ, Hypertens Unit, Madrid, Spain
[4] GlaxoSmithKline, Dept Med, Madrid, Spain
来源
AMERICAN JOURNAL OF MEDICINE | 2006年 / 119卷 / 04期
关键词
insulin resistance; hypertension; type; 2; diabetes; impaired fasting glucose; impaired glucose tolerance; left ventricular hypertrophy;
D O I
10.1016/j.amjmed.2005.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Arterial hypertension is an insulin-resistant condition that has been associated with an increased incidence of diabetes. We assessed the prevalence of glucose abnormalities in a population of patients with essential hypertension. Methods: In this cross-sectional study, 420 consecutively referred essential hypertensive patients were studied at 16 hypertension clinics in university and community hospitals of Spain. Fasting and 2-hour plasma glucose and insulin levels were determined in nondiabetic patients. Results: An abnormal glucose metabolism was diagnosed in 68.5% (95% confidence interval [CI], 63.7%-72.9%) of the patients. Isolated insulin resistance, defined by a homeostasis model assessment-estimated insulin resistance (HOMA-IR) equal to or above 3.8, was shown in 9.3% (95% CI, 6.7%-12.5%); impaired fasting glucose in 11.2% (95% CI, 8.6%-14.7%); impaired glucose tolerance in 22.5% ( 95% CI, 18.5%-26.9%); silent undiagnosed type 2 diabetes in 11.5% (95% CI, 8.6%-14.5%); and known diabetes mellitus in 13.9% (95% CI, 10.4%-17.2%) of the patients. According to the European Group for the Study of Insulin Resistance and the Adult Treatment Program III criteria, the metabolic syndrome was diagnosed in 41.5% (95% CI, 35.9%-47.3%) and 47.9% (95% CI, 43.1%-52.8%) of the patients, respectively. The prevalence of left ventricular hypertrophy (defined by a left ventricular mass index [LVMI] >125 g/m(2)) was 44.2%. The relation between HOMA-IR and LVMI was statistically nonsignificant, and the LVMI values in the HOMA-IR quartiles were similar. Only 27 patients (6.4%) showed good control of cardiovascular risk factors. In most patients (273, 65%; 95% CI, 60.3%-69.4%) 2 or more cardiovascular risk factors were identified as not being under control. Conclusions: Two thirds of the patients attending hypertension clinics with essential hypertension show an abnormal glucose metabolism. The metabolic syndrome can be identified in a substantial number of these patients, and 2 or more cardiovascular risk factors are not controlled in the majority of patients. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 50 条
  • [31] Effects of azelnidipine on uric acid metabolism in patients with essential hypertension
    Miyazaki, Satoshi
    Hamada, Toshihiro
    Hirata, Shigemasa
    Ohtahara, Akira
    Mizuta, Einosuke
    Yamamoto, Yasutaka
    Kuwabara, Masanari
    Nosaka, Yoshihito
    Igawa, Osamu
    Ogino, Kazuhide
    Kato, Masahiko
    Yoshida, Akio
    Ninomiya, Haruaki
    Cheng, Jidong
    Moriwaki, Yuji
    Yamamoto, Kazuhiro
    Hisatome, Ichiro
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2014, 36 (07) : 447 - 453
  • [32] CATECHOLAMINE METABOLISM IN ESSENTIAL HYPERTENSION
    BRUNJES, S
    ANNALS OF INTERNAL MEDICINE, 1964, 61 (04) : 811 - +
  • [33] CATECHOLAMINE METABOLISM IN ESSENTIAL HYPERTENSION
    MENDLOWITZ, M
    WOLF, RL
    GITLOW, SE
    AMERICAN HEART JOURNAL, 1970, 79 (03) : 401 - +
  • [34] PRELIMINARY OBSERVATIONS ON THE EFFECTS OF PARENTERAL RESERPINE ON CEREBRAL BLOOD FLOW, OXYGEN AND GLUCOSE METABOLISM, AND ELECTROENCEPHALOGRAMS OF PATIENTS WITH ESSENTIAL HYPERTENSION
    HAFKENSCHIEL, JH
    SELLERS, AM
    KING, GA
    THORNER, MW
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1955, 61 (01) : 78 - 84
  • [35] Olmesartan improves glucose metabolism and insulin sensitivity in patients with essential hypertension more than does a calcium channel blocker
    Moniwa, Norihito
    Yoshida, Hideaki
    Agata, Jun
    Miyazaki, Yoshinori
    Higashiura, Katsuhiro
    Ura, Nobuyuki
    Shimamoto, Kazuaki
    JOURNAL OF HYPERTENSION, 2006, 24 : 136 - 136
  • [36] Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension
    Shionoiri, H
    Takasaki, I
    Naruse, M
    Nagamoti, I
    Himeno, H
    Ito, T
    Ohtomi, S
    Hata, T
    Shindo, K
    Mikami, H
    Ogihara, T
    Ishii, M
    CLINICAL THERAPEUTICS, 1995, 17 (06) : 1126 - 1135
  • [37] Cortisol secretion and abnormalities of glucose metabolism in nondiabetic patients with hypertension
    Brosolo, Gabriele
    Da Porto, Andrea
    Bulfone, Luca
    Vacca, Antonio
    Bertin, Nicole
    Catena, Cristiana
    Sechi, Leonardo A.
    JOURNAL OF HYPERTENSION, 2024, 42 (02) : 227 - 235
  • [38] RENAL DENERVATION IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION
    Mahfoud, F.
    Ukena, C.
    Cremers, B.
    Kindermann, I.
    Kindermann, M.
    Sobotka, P. A.
    Schlaich, M.
    Boehm, M.
    JOURNAL OF HYPERTENSION, 2010, 28 : E219 - E219
  • [39] Abnormal glycemic metabolism in essential hypertension.: Role of the oral glucose tolerance test
    Garíca-Puig, J
    Luque-Otero, M
    Ruilope-Urioste, LM
    MEDICINA CLINICA, 2006, 126 (03): : 116 - 117
  • [40] Abnormal glycemic metabolism in essential hypertension.: Role of the an oral glucose tolerance test
    Stiefel, P
    Miranda, ML
    Muñiz, O
    Nieto, MD
    Jiménez, L
    Villar, J
    MEDICINA CLINICA, 2005, 125 (05): : 179 - 181